Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
5.79
+0.13 (2.30%)
At close: Jun 20, 2025, 4:00 PM
5.80
+0.01 (0.17%)
After-hours: Jun 20, 2025, 5:57 PM EDT
Bolt Biotherapeutics Employees
Bolt Biotherapeutics had 52 employees as of December 31, 2024. The number of employees decreased by 48 or -48.00% compared to the previous year.
Employees
52
Change (1Y)
-48
Growth (1Y)
-48.00%
Revenue / Employee
$69,962
Profits / Employee
-$1,218,212
Market Cap
11.10M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52 | -48 | -48.00% |
| Dec 31, 2023 | 100 | 6 | 6.38% |
| Dec 31, 2022 | 94 | 3 | 3.30% |
| Dec 31, 2021 | 91 | 26 | 40.00% |
| Dec 31, 2020 | 65 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
BOLT News
- 5 weeks ago - Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - GlobeNewsWire
- 7 weeks ago - Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire
- 3 months ago - Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire
- 3 months ago - Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Bolt Biotherapeutics to Participate in Upcoming March Conferences - GlobeNewsWire
- 4 months ago - Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc. - GlobeNewsWire